Dr. Bekaii-Saab Discusses the FDA Approval of Lenvatinib in HCC

Tanios Bekaii-Saab, MD
Published: Thursday, Aug 16, 2018



Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the FDA approval of lenvatinib (Lenvima) as a frontline systemic treatment for patients with advanced hepatocellular carcinoma (HCC).

This approval was based on data from the phase III REFLECT trial, in which the multikinase inhibitor lenvatinib showed noninferiority to sorafenib (Nexavar). The median overall survival was 13.6 months with lenvatinib compared with 12.3 months for the first-line standard of care sorafenib (HR, 0.92; 95% CI, 0.79-1.06). The median progression-free survival was 7.4 versus 3.7 months for lenvatinib and sorafenib, respectively (HR, 0.66; 95% CI: 0.57-0.77; P <.0001). Time-to-progression was 8.9 months for lenvatinib compared with 3.7 months for sorafenib (HR, 0.63; 95% CI, 0.53-0.73; <.0001).

Lenvatinib will now be available as an option for the frontline treatment of patients with unresectable HCC. 


Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the FDA approval of lenvatinib (Lenvima) as a frontline systemic treatment for patients with advanced hepatocellular carcinoma (HCC).

This approval was based on data from the phase III REFLECT trial, in which the multikinase inhibitor lenvatinib showed noninferiority to sorafenib (Nexavar). The median overall survival was 13.6 months with lenvatinib compared with 12.3 months for the first-line standard of care sorafenib (HR, 0.92; 95% CI, 0.79-1.06). The median progression-free survival was 7.4 versus 3.7 months for lenvatinib and sorafenib, respectively (HR, 0.66; 95% CI: 0.57-0.77; P <.0001). Time-to-progression was 8.9 months for lenvatinib compared with 3.7 months for sorafenib (HR, 0.63; 95% CI, 0.53-0.73; <.0001).

Lenvatinib will now be available as an option for the frontline treatment of patients with unresectable HCC. 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication
x